Frank Watanabe
Viewpoint: In the name of equity, Democrats try to limit drug patent rights. Here’s why that could derail US bioinnovation and hurt the most vulnerable
When it comes to our currently world-leading biotechnology industry, our leaders are repeating many of the same mistakes ...